Home » 5 Monster Biotech Breakouts, Plus Intel, Texas Instruments, and Amazon

5 Monster Biotech Breakouts, Plus Intel, Texas Instruments, and Amazon

5 Monster Biotech Breakouts, Plus Intel, Texas Instruments, and Amazon

5 Monster Biotech Breakouts, Plus Intel, Texas Instruments, and Amazon

MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN SHARES OF CELG
© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 795 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

A bit of bore today with the S&P 500 going nowhere. Fine by me, as we can use a couple of days of consolidation.  Again, the bullish narrative for stocks remains unchanged.

spx

Biotech

Biotech IBB ETF is getting closer to that breakout, inching closer to $120.

biotech

Celgene

Celgene is continuing its road to recovering and is once again tracking towards $97. That RSI continue to trend nicely higher as well.

celg

Gilead

Gilead had a setback, but stopped falling at support around $72.50. Now it likely makes its second attempt at rising to $82.50.

gilead

Regeneron

Regeneron is making its second attempt at breaking out and rising above $393.50. It may be on its way to $430.

regeneron

Nektar

Nektar looks to be on its way to $70. Maybe $83 and a gap fill? Let’s see if it get to $70 first.

nektar

Incyte

Incyte looks like it close to break out, that could send it back to $80.

incy

Intel

Intel is working hard trying to break out, but I think it may be too soon to say shares have. I think it needs to clear $51 before it is out of the woods.

intel

TI

Texas Instruments does look rather strong here. A push to $121 appears to be on the way.

texas instruments

Amazon

Amazon is still struggling at the upper end of the trading wedge. Still not out of the danger zone yet. Look at that RSI though, lower highs,  bearish divergence? Perhaps.

amazon

Sorry it was so technical analysis heavy today, but way to hot here in NY and I’m feeling a bit lazy today.

-Mike

Member Services

Michael Kramer is the Founder of Mott Capital and the creator of Reading the Markets.

I started learning to invest when I was 16 years old. At 40, I have pieced together a long career on Wall Street, working as an analyst, and a domestic and international equity trader at two multi-billion dollar equity firms.

I started Mott Capital in 2014 to follow a passion and dream of being in control of my career path.

The idea behind Reading the Markets was to help both individual and institutional investors benefit from my experience in the business and my unique approach to dissecting stocks and the markets, which helped me become a great trader.

Reading the Markets is a combination of technical, fundamental, a macro market analysis, trying to piece together the clues the market is sending in its future direction.

Reading the Markets is unique, in that the video does not only serve as a means to deliver the content but to interact, making it a personal learning experience, while also showing the user how I go about finding my research and how you can use the process to do your work.

I want this product not only to be profitable and enjoyable but also affordable.

Here are some of the recent videos:

Biotech And Semis Breaking Out?

FAANG’s Not Out Of The Woods But Getting Better

Verizon Nears Multiyear Break Out As 5G Data Speeds Near

Amazon May Plunge 10%

The Dollar May Soon Wreak Havoc On Oil And Gold

Inflation Runs Rampant Only In Fantasyland And That Is Good For Stocks

Tesla May Be Going Higher Regardless Of The Bid

Why The S&P 500 May Rise To 3,500

Why Apple May Rise By 50%

Facebook’s Growth Issue

Netflix Is Not Broken, Plus S&P May Rise To 3,000 Sooner Than You Think

Photo Credit Via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

#biotech #celgene #sp500 #nektar #regeneron #intel #ti #amazon #gilead